EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Predictors of relapses in patients with chronic inflammatory demyelinating polyneuropathy receiving subcutaneous immunoglobulin therapy – a post-hoc analysis

Lars K Markvardsen iD, Helga Haahr-Lillevang iD, Tobias Sejbæk, Tina Parkner, Søren H Sindrup, Johannes Jakobsen, Henning Andersen

Journal of Neuromuscular Diseases · 2026-11 · 13 (6) · 1406-1412

DOI: 10.1177/22143602261442297 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neuromuscular Diseases, online erschienen am 29.04.2026. Verfasst von Lars K Markvardsen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Aarhus University Hospital, Aarhus, Denmark. Hauptthemen laut MEDLINE: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Immunoglobulins, Immunologic Factors. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Danish Regions.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In a previous study we demonstrated that standardized tapering off subcutaneous immunoglobulin (SCIG) is a safe way to identify remission in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). However, clinical characteristics and dosage of SCIG in patients in remission are unknown.

Methods

In the present study, we aimed to identify characteristics of patients in remission during tapering off SCIG. Participants received a stable SCIG dosage and followed a standardized tapering off regimen providing 90%, 75%, 50%, 25% and 0% of the initial dose, every 12 th week, pending no deterioration occurred. All patients were followed for 164 weeks after inclusion and were evaluated with disability scores, quality of life score (EQ-5D-5L), blood samples and clinical examination.

Results

Receiving a dosage of SCIG >25 g/week predicts a higher risk of relapse, OR 6.3 (95CI 1.8-20.2)(p = 0.004), but not when considering body weight (SCIG >0.3 g/kg/week), OR 3.3 (95CI 1.0-9.7)(p = 0.05). Moreover, a higher level of serum NfL OR 8.2 (95CI 1.1-93.3)(p = 0.04) predicts relapse. Low scores on EQ-5D-5L at baseline predicted increased risk of relapse. Serum calprotectin was similar in patients with relapse and in remission. Evaluating measurements from baseline, final visit and the last visit before final visit (LVBF), we found that deterioration in clinical performance could not be predicted at LVBF based on any of the tests performed.

Conclusion

Patients experiencing a relapse of CIDP during tapering off SCIG seem to receive a total higher dosage of immunoglobulin and had a higher sNfL prior to tapering off compared to patients without a relapse.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingImmunoglobulinsImmunologic FactorsHumansFemaleMaleMiddle AgedRecurrenceAgedInjections, SubcutaneousQuality of LifeAdultInfusions, Subcutaneous

Stichwörter der Autor:innen

chronic inflammatory demylienating polyneuropathydisabilityneurofilament light chainquality of lifesubcutaneous immunoglobulin

Substanzen

ImmunoglobulinsImmunologic Factors

Autor:innen und Institutionen

  • Department of Neurology, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Neurology, Aalborg University Hospital, Aalborg, Denmark.
  • Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
  • Department of Neurology, Esbjerg Hospital, Esbjerg, Denmark.
  • Department of Biochemistry, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Neurology, Odense University Hospital, Odense, Denmark.

ORCID-Profile: Lars K Markvardsen, Helga Haahr-Lillevang

Förderung

  • Danish Regions

Zitieren

APA

Markvardsen, L. K., Haahr-Lillevang, H., Sejbæk, T., Parkner, T., Sindrup, S. H., Jakobsen, J., & Andersen, H. (2026). Predictors of relapses in patients with chronic inflammatory demyelinating polyneuropathy receiving subcutaneous immunoglobulin therapy – a post-hoc analysis. Journal of Neuromuscular Diseases, 13(6), 1406-1412. https://doi.org/10.1177/22143602261442297

Vancouver

Markvardsen LK, Haahr-Lillevang H, Sejbæk T, Parkner T, Sindrup SH, Jakobsen J, et al. Predictors of relapses in patients with chronic inflammatory demyelinating polyneuropathy receiving subcutaneous immunoglobulin therapy – a post-hoc analysis. Journal of Neuromuscular Diseases. 2026;13(6):1406-1412. doi:10.1177/22143602261442297

BibTeX
@article{Markvardsen2026,
  author = {Markvardsen, Lars K and Haahr-Lillevang, Helga and Sejbæk, Tobias and Parkner, Tina and Sindrup, Søren H and Jakobsen, Johannes and Andersen, Henning},
  title = {Predictors of relapses in patients with chronic inflammatory demyelinating polyneuropathy receiving subcutaneous immunoglobulin therapy – a post-hoc analysis},
  journal = {Journal of Neuromuscular Diseases},
  year = {2026},
  volume = {13},
  number = {6},
  pages = {1406--1412},
  doi = {10.1177/22143602261442297}
}
Kostenlos starten →